BMS reports four-year data from psoriasis treatment extension trial
Bristol Myers Squibb (BMS) has revealed four-year data from the POETYK PSO long-term extension (LTE) trial of Sotyktu in treating…
Bristol Myers Squibb (BMS) has revealed four-year data from the POETYK PSO long-term extension (LTE) trial of Sotyktu in treating…
InnoCare Pharma has announced the completion of subject enrolment in the Phase II clinical trial of ICP-488, a treatment designed…
US pharmaceutical company Merck & Co Inc (MSD) has discontinued a Phase III trial investigating a co-formulation of vibostolimab and…
Singapore-based biopharmaceutical company ASLAN Pharmaceuticals has announced positive interim data from its Phase II TREK-DX study of eblasakimab, a drug…
The epidemiology of atopic dermatitis (AD) is heterogeneous across countries and age groups. Traditionally, AD in South Korea has always…
This week on Pipeline Moves, we kick off by looking at a Phase III trial completion of Pfizer’s influenza vaccine…
ARS Pharmaceuticals expects to launch neffy (epinephrine nasal spray) in H2 2024, for which the company plans to submit a…
Previously in the literature, an association between those with vitiligo and an increased risk of developing osteoporosis has been speculated.…
Aquestive Therapeutics has revealed topline data from the Phase III pharmacokinetic (PK) study of its anaphylactic drug, Anaphylm (epinephrine) sublingual…
Sanofi has announced encouraging findings from the second part of a study with the OX40 antibody amlitelimab, which showed sustained…